Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.

Area of Science:

• Oncology
• Molecular Biology
• Cell Cycle Regulation

Background:

• Cancer is fundamentally a disease of uncontrolled cell proliferation driven by molecular pathway dysregulation.
• The G1/S phase transition in the cell cycle is a critical checkpoint for cell division, regulated by cyclin-dependent kinases (CDKs) and the retinoblastoma protein (RB).
• Cyclin-dependent kinases CDK4 and CDK6 (CDK4/6) complex with cyclin D to phosphorylate and inhibit RB, leading to E2F transcription factor activation and S phase entry.

Purpose of the Study:

• To review recent advancements in targeting the G1/S phase transition pathway for cancer therapy.
• To explore the potential of novel CDK inhibitors and other pathway modulators as single agents or combination therapies.
• To discuss alternative strategies beyond current ATP-competitive CDK4/6 inhibitors for opposing cancer growth.

Main Methods:

• Review of biochemical and genetic studies elucidating cell cycle regulation.
• Analysis of the development and application of small molecule ATP-competitive CDK4/6 inhibitors.
• Examination of recently developed inhibitors targeting CDKs and other G1/S pathway components.

Main Results:

• CDK4/6 inhibitors are established treatments for certain breast cancers by blocking the G1/S transition.
• Limitations of current CDK4/6 inhibitors necessitate the exploration of alternative therapeutic approaches.
• Emerging inhibitors targeting CDKs and related pathways show promise for cancer treatment.

Conclusions:

• Targeting the G1/S transition is a validated strategy in cancer therapy.
• Novel inhibitors offer potential for overcoming limitations of existing treatments.
• Combination therapies involving new G1/S pathway modulators may enhance efficacy against human cancers.